KR102227629B1 - 치환된 잔틴 및 그것의 사용 방법 - Google Patents

치환된 잔틴 및 그것의 사용 방법 Download PDF

Info

Publication number
KR102227629B1
KR102227629B1 KR1020157029667A KR20157029667A KR102227629B1 KR 102227629 B1 KR102227629 B1 KR 102227629B1 KR 1020157029667 A KR1020157029667 A KR 1020157029667A KR 20157029667 A KR20157029667 A KR 20157029667A KR 102227629 B1 KR102227629 B1 KR 102227629B1
Authority
KR
South Korea
Prior art keywords
compound
trpc5
alkyl
compounds
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157029667A
Other languages
English (en)
Korean (ko)
Other versions
KR20150133233A (ko
Inventor
버트란드 쉬나드
랜들 갈라슌
랜들 갈라šœ
Original Assignee
하이드라 바이오사이언시스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50680155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102227629(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하이드라 바이오사이언시스, 엘엘씨 filed Critical 하이드라 바이오사이언시스, 엘엘씨
Publication of KR20150133233A publication Critical patent/KR20150133233A/ko
Application granted granted Critical
Publication of KR102227629B1 publication Critical patent/KR102227629B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Medicinal Preparation (AREA)
KR1020157029667A 2013-03-15 2014-03-14 치환된 잔틴 및 그것의 사용 방법 Active KR102227629B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789724P 2013-03-15 2013-03-15
US61/789,724 2013-03-15
PCT/US2014/027920 WO2014143799A2 (en) 2013-03-15 2014-03-14 Substituted xanthines and methods of use thereof

Publications (2)

Publication Number Publication Date
KR20150133233A KR20150133233A (ko) 2015-11-27
KR102227629B1 true KR102227629B1 (ko) 2021-03-16

Family

ID=50680155

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029667A Active KR102227629B1 (ko) 2013-03-15 2014-03-14 치환된 잔틴 및 그것의 사용 방법

Country Status (31)

Country Link
US (7) US9359359B2 (https=)
EP (1) EP2970303B3 (https=)
JP (1) JP6360149B2 (https=)
KR (1) KR102227629B1 (https=)
CN (2) CN107082782B (https=)
AU (1) AU2014228206C1 (https=)
CA (1) CA2899646C (https=)
CL (1) CL2015002738A1 (https=)
CY (1) CY1119042T1 (https=)
DK (1) DK2970303T6 (https=)
EA (1) EA028815B1 (https=)
ES (1) ES2636835T7 (https=)
HR (1) HRP20170840T4 (https=)
HU (1) HUE033528T4 (https=)
IL (1) IL240216B (https=)
LT (1) LT2970303T (https=)
MX (1) MX370372B (https=)
MY (1) MY189912A (https=)
NZ (1) NZ711718A (https=)
PE (1) PE20151779A1 (https=)
PH (1) PH12015502141B1 (https=)
PL (1) PL2970303T6 (https=)
PT (1) PT2970303T (https=)
RS (1) RS56066B2 (https=)
SG (1) SG11201506479TA (https=)
SI (1) SI2970303T1 (https=)
TW (1) TWI609867B (https=)
UA (1) UA117470C2 (https=)
UY (1) UY35488A (https=)
WO (1) WO2014143799A2 (https=)
ZA (1) ZA201505414B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173750B2 (en) 2009-04-23 2012-05-08 ATRP Solutions, Inc. Star macromolecules for personal and home care
CN107082782B (zh) 2013-03-15 2020-03-20 海德拉生物科学有限责任公司 取代的黄嘌呤及其使用方法
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
GB2553685B (en) 2015-03-27 2020-06-10 Latvian Inst Organic Synthesis Novel ethynylxanthines for use as inhibitors of matrix metalloproteinases and angiogenesis
CA2989161C (en) 2015-03-27 2022-03-01 Latvian Institute Of Organic Synthesis Ethynylxanthines, preparation and use for cancer treatment
WO2016159747A1 (en) 2015-03-27 2016-10-06 Latvian Institute Of Organic Synthesis Ethynylxanthines, preparation and use as calcium ion channel modulators
BR112017021386A2 (pt) * 2015-04-08 2018-07-03 Lewis And Clark Pharmaceuticals, Inc. carbamatos de alquinila com xantina substituída/carbamatos reversos como antagonistas de a2b.
CN107118586A (zh) * 2016-02-24 2017-09-01 中国科学技术大学 含氮杂环基取代的烯类化合物的用途
GB201702160D0 (en) * 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
CN110573509B (zh) * 2017-02-28 2023-05-26 北京生命科学研究所 Mlkl抑制剂
US11666577B2 (en) * 2017-02-28 2023-06-06 National Institute Of Biological Sciences, Beijing MLKL inhibitors
DK3652176T3 (da) * 2017-07-11 2022-01-17 Boehringer Ingelheim Int Substituerede xanthinderivater
CA3093084A1 (en) * 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
US12291532B2 (en) 2018-12-12 2025-05-06 Boehringer Ingelheim International Gmbh Substituted xanthines as modulators of TRPC5 activity
HUE064908T2 (hu) * 2018-12-12 2024-04-28 Boehringer Ingelheim Int Szubsztituált xantinszármazékok
CN112979651B (zh) * 2021-04-09 2022-02-01 南京纽邦生物科技有限公司 一种副黄嘌呤的制备方法
CN113354646B (zh) * 2021-07-06 2022-11-15 南开大学 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用
CN115636831B (zh) * 2022-10-27 2024-11-08 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物
WO2024133476A1 (en) 2022-12-20 2024-06-27 Boehringer Ingelheim International Gmbh Process for the preparation of 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione
WO2024153028A1 (zh) * 2023-01-20 2024-07-25 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
WO2024165540A1 (en) 2023-02-06 2024-08-15 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 7-(4-chlorobenzyl)-1-(3-hydroxypropyl)-3-methyl-8-(3-(trifluoromethoxy)-phenoxy)-3,7-dihydro-1h-purine-2,6-dione
WO2024164818A1 (zh) * 2023-02-08 2024-08-15 中国科学院上海药物研究所 黄嘌呤类化合物及其用途
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035148A1 (en) 1998-01-02 1999-07-15 Cell Therapeutics, Inc. Compounds for increased bioavailability
WO2008011518A2 (en) 2006-07-19 2008-01-24 Diakine Therapeutics, Inc. Encapsulation system
US20090018148A1 (en) 2005-12-07 2009-01-15 Ucb Pharma, S.A. Xanthine Derivatives, Processes For Preparing Them And Their Uses
WO2011114184A1 (en) 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
JP2013023102A (ja) 2011-07-22 2013-02-04 Panasonic Corp 列車情報提供システム
WO2013023102A1 (en) 2011-08-09 2013-02-14 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4304650A1 (de) * 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
JP4191269B2 (ja) 1996-05-17 2008-12-03 興和株式会社 新規なアニリド化合物及びこれを含有する医薬
JPH10318487A (ja) 1997-05-16 1998-12-04 Mitsubishi Gas Chem Co Inc 真空断熱材用ゲッタ
US6187780B1 (en) * 1998-04-16 2001-02-13 Boehringer Ingelheim Pharma Kg Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
CA2369981A1 (en) * 1999-04-09 2000-10-19 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
RU2003103103A (ru) * 2000-07-04 2004-08-20 Ново Нордиск А/С (DK) Гетероциклические соединения, которые являются ингибиторами фермента dpp-iv
CN1486302A (zh) 2000-12-07 2004-03-31 CV���ƹ�˾ 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶
EP1368349B1 (de) * 2001-02-24 2007-02-14 Boehringer Ingelheim Pharma GmbH & Co.KG Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
ATE520694T1 (de) * 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
CA2524778C (en) * 2003-05-06 2013-01-29 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
JP2007511528A (ja) 2003-11-13 2007-05-10 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 心肥大および心不全の処置としてのｔｒｐチャネル阻害方法
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
US8143254B2 (en) 2005-02-18 2012-03-27 Cornell Research Foundation, Inc. Methods for modulating ion channels
ES2401128T3 (es) * 2005-08-10 2013-04-17 Glaxosmithkline Llc Derivados de xantina como agonistas selectivos de HM74A
US20080214563A1 (en) 2005-09-06 2008-09-04 Mui Cheung Benzimidazole Thiophene Compounds As Plk Modulators
AU2006327181A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
WO2007084728A2 (en) 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
WO2007101213A2 (en) 2006-02-28 2007-09-07 Kalypsys, Inc. Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
US20120148604A1 (en) 2009-08-20 2012-06-14 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
WO2012050641A2 (en) 2010-06-08 2012-04-19 Hydra Biosciences, Inc Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents
CN103121970B (zh) 2012-12-04 2015-04-29 中国科学院昆明植物研究所 苯并咪唑及其衍生物，其药物组合物及其在制备抗抑郁药物中的应用
CN107082782B (zh) 2013-03-15 2020-03-20 海德拉生物科学有限责任公司 取代的黄嘌呤及其使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035148A1 (en) 1998-01-02 1999-07-15 Cell Therapeutics, Inc. Compounds for increased bioavailability
US20090018148A1 (en) 2005-12-07 2009-01-15 Ucb Pharma, S.A. Xanthine Derivatives, Processes For Preparing Them And Their Uses
WO2008011518A2 (en) 2006-07-19 2008-01-24 Diakine Therapeutics, Inc. Encapsulation system
US20090269313A1 (en) 2006-07-19 2009-10-29 Diakine Therapeutics, Inc. Encapsulation system
WO2011114184A1 (en) 2010-03-15 2011-09-22 Glenmark Pharmaceuticals S.A. Amides of heterocyclic compounds as trpa1 inhibitors
JP2013023102A (ja) 2011-07-22 2013-02-04 Panasonic Corp 列車情報提供システム
WO2013023102A1 (en) 2011-08-09 2013-02-14 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1

Also Published As

Publication number Publication date
US20180244674A1 (en) 2018-08-30
TWI609867B (zh) 2018-01-01
EP2970303B3 (en) 2018-08-01
JP6360149B2 (ja) 2018-07-18
EP2970303B1 (en) 2017-05-10
PH12015502141A1 (en) 2016-01-25
US11958854B2 (en) 2024-04-16
CN107082782B (zh) 2020-03-20
WO2014143799A3 (en) 2014-11-06
US20170305910A1 (en) 2017-10-26
CL2015002738A1 (es) 2016-06-10
MY189912A (en) 2022-03-21
US20160237089A1 (en) 2016-08-18
TW201533044A (zh) 2015-09-01
RS56066B2 (sr) 2018-09-28
WO2014143799A2 (en) 2014-09-18
IL240216A0 (en) 2015-09-24
ES2636835T3 (es) 2017-10-09
HUE033528T2 (hu) 2017-12-28
IL240216B (en) 2018-11-29
RS56066B1 (sr) 2017-10-31
ZA201505414B (en) 2016-03-30
US10399982B2 (en) 2019-09-03
CA2899646A1 (en) 2014-09-18
EA028815B1 (ru) 2018-01-31
PL2970303T6 (pl) 2018-12-31
UY35488A (es) 2014-10-31
DK2970303T6 (en) 2018-10-08
SG11201506479TA (en) 2015-09-29
MX2015011617A (es) 2016-04-25
CN105143229A (zh) 2015-12-09
CN105143229B (zh) 2017-06-30
ES2636835T7 (es) 2018-11-20
PH12015502141B1 (en) 2018-10-12
CY1119042T1 (el) 2018-01-10
CN107082782A (zh) 2017-08-22
MX370372B (es) 2019-12-11
AU2014228206B2 (en) 2018-05-10
AU2014228206C1 (en) 2018-10-25
PE20151779A1 (es) 2015-11-20
PL2970303T3 (pl) 2017-08-31
HUE033528T4 (en) 2018-05-02
NZ711718A (en) 2020-05-29
CA2899646C (en) 2021-08-31
BR112015021164A8 (pt) 2019-12-03
LT2970303T (lt) 2017-07-25
SI2970303T1 (sl) 2017-08-31
WO2014143799A9 (en) 2014-12-24
HK1217329A1 (zh) 2017-01-06
EP2970303A2 (en) 2016-01-20
EA201591615A1 (ru) 2016-05-31
DK2970303T3 (en) 2017-06-26
AU2014228206A1 (en) 2015-09-24
US20230040259A1 (en) 2023-02-09
WO2014143799A4 (en) 2015-02-12
EP2970303B9 (en) 2017-09-20
BR112015021164A2 (pt) 2017-07-18
US11208409B2 (en) 2021-12-28
US20190322667A1 (en) 2019-10-24
UA117470C2 (uk) 2018-08-10
US9359359B2 (en) 2016-06-07
HRP20170840T1 (hr) 2017-09-08
DK2970303T5 (en) 2018-01-02
HRP20170840T4 (hr) 2018-11-16
US20140275071A1 (en) 2014-09-18
PT2970303T (pt) 2017-06-23
US20250034143A1 (en) 2025-01-30
US9969736B2 (en) 2018-05-15
KR20150133233A (ko) 2015-11-27
JP2016513717A (ja) 2016-05-16

Similar Documents

Publication Publication Date Title
KR102227629B1 (ko) 치환된 잔틴 및 그것의 사용 방법
EP2970316B1 (en) Substituted xanthines and methods of use thereof
EP3180340B1 (en) Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
EP3180342B1 (en) Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
HK1240215A1 (en) Substituted xanthines and methods of use thereof
BR112015021164B1 (pt) Composto de xantina substituída e seu sal
HK1240215B (zh) 取代的黄嘌呤及其使用方法
HK1217329B (en) Substituted xanthines and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151015

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190215

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20200226

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200612

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210111

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210309

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210310

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240214

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250206

Start annual number: 5

End annual number: 5